ONCOR PRICING INFORM HER-2/NEU BREAST CANCER RECURRENCE TEST AT $100; FIRST QUARTER LAUNCH ANTICIPATED FOLLOWING DEC. 30 PMA APPROVAL
This article was originally published in The Gray Sheet
Oncor plans to offer its Inform HER-2/neu gene-based DNA test for predicting recurrence of breast cancer at a price of about $100 per determination to qualified testing laboratories following roll-out in the first quarter of 1998.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.